InvestorBrandNetwork (IBN) Content Platform

• Brera Holdings, an Ireland-based, international holding company focused on expanding its global portfolio of men’s and women’s sports clubs, has reiterated its commitment to growing women’s soccer globally
• In a joint report co-authored with leading global law firm Clifford Chance LLP, Brera noted the benefits of its MCO model and the opportunity it presents for the growth of the sport
• Women’s soccer is experiencing unprecedented growth, with record-breaking attendance, extensive media coverage, and increasing investment from celebrities and corporations
• Brera is strategically positioned to capitalize on this momentum, leveraging its MCO model to drive sustainable growth and enhance shareholder value

Brera Holdings (NASDAQ: BREA), an Ireland-based, international holding company focused on expanding its global portfolio of men’s and women’s sports clubs through a multi-club ownership (“MCO”) approach, has reiterated its commitment to advancing women’s soccer.

In a joint report co-authored with leading global law firm Clifford Chance LLP, Brera outlines the benefits of MCO models in women’s soccer, the opportunity it presents for the growth of the sport, and for…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to BREA are available in the company’s newsroom at https://ibn.fm/BREA

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
Editor@InvestorWire.com

Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, today announced its recent accomplishments and financial results for the year ended Dec. 31, 2024. “We remain highly focused on advancing our multiple clinical programs as we work towards achieving a number of important and potentially transformational development milestones, including top-line results in 2026 for our actively enrolling confirmatory Phase 3 placebo-controlled study evaluating HyBryte(TM) (synthetic hypericin) in the treatment of early-stage cutaneous T-cell lymphoma (‘CTCL’),” stated Christopher J. Schaber, PhD, president and chief executive officer of Soligenix. “In the second half of this year, we also anticipate reporting top-line results from our ongoing Phase 2 studies for SGX945 (dusquetide) in Behçet’s disease and SGX302 (synthetic hypericin) in mild-to-moderate psoriasis.”

To view the full press release, visit https://ibn.fm/mKGrJ

About Soligenix Inc.

Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Its Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte(TM) (“SGX301” or synthetic hypericin sodium) as a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma (“CTCL”). With successful completion of the second Phase 3 study, regulatory approvals will be sought to support potential commercialization worldwide. Development programs in this business segment also include expansion of synthetic hypericin (“SGX302”) into psoriasis, Soligenix’s first-in-class innate defense regulator (“IDR”) technology, dusquetide (“SGX942”) for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer, and (“SGX945”) in Behçet’s disease.

The company’s Public Health Solutions business segment includes development programs for RiVax(R), its ricin toxin vaccine candidate, as well as its vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax(TM), its vaccine candidate for the prevention of COVID-19 (caused by SARS-CoV-2). The development of Soligenix’s vaccine programs incorporates the use of its proprietary heat stabilization platform technology, known as ThermoVax(R). To date, this business segment has been supported with government grant and contract funding from the National Institute of Allergy and Infectious Diseases (“NIAID”), the Defense Threat Reduction Agency (“DTRA”) and the Biomedical Advanced Research and Development Authority (“BARDA”).

For more information, visit the company’s website at www.Soligenix.com.

NOTE TO INVESTORS: The latest news and updates relating to SNGX are available in the company’s newsroom at https://ibn.fm/SNGX

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
Editor@InvestorWire.com

InvestorWire is powered by IBN

McEwen Mining (NYSE: MUX) (TSX: MUX) through its founder Rob McEwen, has reaffirmed confidence in Goliath Resources (TSX-V: GOT) (OTCQB: GOTRF) by participating in recent warrant exercises, contributing to the $3.2 million Goliath has received since Jan. 1. McEwen, who holds approximately 3.9% of Goliath’s shares, joins Crescat Capital (~14.4%) in leveraging deep-in-the-money warrants ahead of key expiration dates in 2025. This influx of capital strengthens Goliath’s financial position as it continues to advance its 100%-controlled Golddigger Property in British Columbia’s Golden Triangle, a prolific mining district known for major discoveries. Goliath still holds nearly 6.4 million outstanding warrants representing over $6.3 million in potential near-term funding, with $3.6 million worth expiring by May 16.

To view the full press release, visit https://ibn.fm/uUClf

About McEwen Mining Inc.

McEwen Mining is a gold and silver producer with operations in Nevada, Canada, Mexico and Argentina. In addition, the company owns approximately 47.7% of McEwen Copper, which is developing the large, advanced-stage Los Azules copper project in Argentina. The company’s goal is to improve the productivity and life of its assets with the objective of increasing the share price and providing a yield. Rob McEwen, chair and chief owner, has a personal investment in the company of $220 million and takes an annual salary of $1. To learn more about the company, visit www.McEwenMining.com.

NOTE TO INVESTORS: The latest news and updates relating to MUX are available in the company’s newsroom at https://ibn.fm/MUX

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
Editor@InvestorWire.com

InvestorWire is powered by IBN

Apple (NASDAQ: AAPL) has lost a key executive from its health division, as Dr. Ricky Bloomfield, formerly the Clinical and Health Informatics Lead, departs to join Oura as its Chief Medical Officer. Bloomfield played a critical role in shaping Apple’s health strategy, including its push into digital health records and wearable health tracking. His move to Oura, a company specializing in smart rings for health monitoring, signals growing competition in the wearable health-tech space, with some analysts seeing it as a potential shift in consumer interest toward ring-based health tracking over smartwatches.

As of the latest trading session, Apple’s stock is trading at $173.25, reflecting an increase of $0.87 (0.50%) from the previous close.

To view the full article, visit https://ibn.fm/02Jls

About Apple Inc.

Apple Inc. is a global leader in consumer electronics, software, and services, known for its flagship products including the iPhone, Mac, iPad, Apple Watch, and AirPods. The company has invested heavily in health and wellness technologies, integrating advanced health monitoring capabilities into its wearable devices. Apple is headquartered in Cupertino, Calif., and operates in markets worldwide.

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
Editor@InvestorWire.com

InvestorWire is powered by IBN

Match Group (NASDAQ: MTCH), s confronting a proxy challenge from hedge fund Anson Funds, which plans to nominate directors to the company’s 10-member board. Anson, holding approximately 0.6% of Match Group’s shares as of December, has been advocating for over a year for the parent company of Tinder, Hinge, and OkCupid to reassess capital allocation, reduce costs, and evaluate its MG Asia business. The hedge fund has also expressed concerns about corporate governance and executive turnover, noting that Match Group has had four CEOs in five years.

As of 10:30 AM EDT on March 20, 2025, Match Group’s stock is trading at $31.63, reflecting an increase of $0.19 (0.60%) from the previous close.​

To view the full article, visit https://ibn.fm/RELFp

About Match Group Inc.

Match Group Inc. is a leading provider of online dating services, operating a portfolio of popular dating platforms including Tinder, Match.com, Hinge, and OkCupid. The company’s mission is to spark meaningful connections for users around the world, offering a variety of products tailored to different preferences and demographics. Match Group is headquartered in Dallas, Texas, and its services are available in over 40 languages across more than 190 countries.​

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
Editor@InvestorWire.com

InvestorWire is powered by IBN

SKYX Platforms (NASDAQ: SKYX), a smart home platform technology company with a portfolio of over 97 issued and pending patents, will host a corporate update call to present its fourth quarter and full-year 2024 financial results. The conference call is scheduled for Monday, March 24, 2025, at 4:30 p.m. Eastern Time. Participating executives include Founder and Executive Chairman Rani Kohen, President Steve Schmidt, Co-CEO Lenny Sokolow, and CFO Marc Boisseau. The call will provide insights into SKYX’s latest advancements, market position, and financial performance.

To view the full press release, visit https://ibn.fm/VW7Di

About SKYX Platforms Corp.

As electricity is a standard in every home and building, our mission is to make homes and buildings become safe-advanced and smart as the new standard. SKYX has a series of highly disruptive advanced-safe-smart platform technologies, with over 97 U.S. and global patents and patent pending applications. Our technologies place an emphasis on high quality and ease of use, while significantly enhancing both safety and lifestyle in homes and buildings. We believe that our products are a necessity in every room in both homes and other buildings in the U.S. and globally. For more information, please visit our website at https://skyplug.com/ or follow us on LinkedIn.

NOTE TO INVESTORS: The latest news and updates relating to SKYX are available in the company’s newsroom at https://ibn.fm/SKYX

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
Editor@InvestorWire.com

InvestorWire is powered by IBN

Fifty 1 Labs (OTC: FITY) a holding company in the health, wellness, and biotech sectors, has acquired Genetic Networks LLC, a biotech firm founded by Dr. Gennaro D’Urso, for $10 million in common shares. As part of the deal, Dr. D’Urso has been appointed CEO and Chairman, while Brandon Spikes remains President and Director. Genetic Networks, known for its GeneScape™ platform, is actively negotiating multi-million dollar contracts with the U.S. Department of Defense to develop biothreat countermeasures. The acquisition enhances FITY’s biotech capabilities, positioning it for rapid growth in personalized medicine, drug repurposing, and biodefense solutions.

To view the full press release, visit https://ibn.fm/UZVtX

About Fifty 1 Labs, Inc.

Fifty 1 Labs, Inc. (OTC: FITY), a Nevada corporation based at 751 North Drive, Melbourne, FL 32934, is a holding company driving innovation in health, wellness, and biotechnology. FITY owns 100% of Genetic Networks LLC, a Delaware-based biotech firm founded in 2015 by Dr. Gennaro D’Urso. Genetic Networks, headquartered in Miami, Florida, develops the GeneScape™ platform, a yeast-based, whole-genome analysis tool that accelerates drug discovery for personalized medicine, biodefense, and wellness applications, with proven success serving major pharma clients like Bristol Myers Squibb. FITY also wholly owns 51, LLC, its sports nutrition subsidiary offering a premium line of supplements—including pre-workout formulas, BCAAs, ION+ Electrolyte Formula, Turmeric Gummies, and Ashwagandha Gummies—designed to enhance athletic performance, recovery, and overall health. The Quickness, Astound NMN, and Drago Knives have been merged out of the company and are no longer part of Fifty 1 Labs, Inc., sharpening FITY’s focus on biotech and wellness synergies to empower individuals and organizations worldwide.

For more information, visit the company’s website at https://fifty1labs.com/

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
Editor@InvestorWire.com

InvestorWire is powered by IBN

Tonix Pharmaceuticals (NASDAQ: TNXP), a biopharmaceutical company developing innovative vaccines, is advancing TNX-801, a live, minimally replicating recombinant virus vaccine designed to protect against mpox. The company reports that TNX-801 has demonstrated single-dose immunity and superior tolerability compared to 20th-century vaccinia vaccines in animal studies. As a new strain of mpox, Clade I, spreads globally—including recent cases in the U.S.—health officials are seeking more effective prevention methods. Tonix believes TNX-801 aligns with the World Health Organization’s criteria for durable, single-dose vaccines that can be administered without special equipment.

To view the full press release, visit https://ibn.fm/hJSRS

About Tonix Pharmaceuticals Holding Corp.

Tonix is a fully integrated biopharmaceutical company focused on transforming therapies for pain management and modernizing solutions for public health challenges. Tonix’s priority is to submit a New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) this month for TNX-102 SL, a product candidate for which two statistically significant phase 3 studies have been completed for the management of fibromyalgia. TNX-102 SL was generally well tolerated in the phase 3 program. The FDA has granted Fast Track designation to TNX-102 SL for the management of fibromyalgia. TNX-102 SL is also being developed to treat acute stress reaction. Tonix recently announced that the U.S. Department of Defense (“DoD”), Defense Threat Reduction Agency (“DTRA”) awarded it a contract for up to $34 million over five years to develop TNX-4200, small molecule broad-spectrum antiviral agents targeting CD45 for the prevention or treatment of infections to improve the medical readiness of military personnel in biological threat environments. Tonix owns and operates a state-of-the art infectious disease research facility in Frederick, Maryland. The company’s Good Manufacturing Practice (“GMP”)-capable advanced manufacturing facility in Dartmouth, Maryland, was purpose-built to manufacture TNX-801, and the GMP suites are ready to be reactivated in case of a national or international emergency. Tonix’s development portfolio is focused on central nervous system (“CNS”) disorders. Tonix’s CNS portfolio includes TNX-1300 (cocaine esterase), a biologic in Phase 2 development designed to treat cocaine intoxication that has Breakthrough Therapy designation. Tonix’s immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease. Tonix Medicines, the company’s commercial subsidiary, markets Zembrace(R) SymTouch(R) (sumatriptan injection) 3 mg and Tosymra(R)(sumatriptan nasal spray) 10 mg for the treatment of acute migraine with or without aura in adults. For more information about the company, please visit www.TonixPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to TNXP are available in the company’s newsroom at https://ibn.fm/TNXP

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
Editor@InvestorWire.com

InvestorWire is powered by IBN

Standard Lithium (NYSE American: SLI) announced the appointment of Karen G. Narwold as an independent director to its board. Narwold brings over 30 years of leadership experience in manufacturing and chemicals, most recently serving as Chief Administrative Officer, General Counsel, and Corporate Secretary at Albemarle Corporation. Her expertise in legal, governance, regulatory, and operational matters is expected to support Standard Lithium’s development of lithium projects in the Smackover formation. Narwold also serves on the board of Ingevity Corporation and chairs its Sustainability & Safety Committee.

To view the full press release, visit https://ibn.fm/PieKK

About Standard Lithium Ltd.

Standard Lithium is a leading near-commercial lithium development company focused on the sustainable development of a portfolio of large, high-grade lithium-brine properties in the United States. The company prioritizes projects characterized by the highest-quality resources, robust infrastructure, skilled labor and streamlined permitting. The company aims to achieve sustainable, commercial-scale lithium production via the application of a scalable and fully integrated direct lithium extraction (“DLE”) and purification process. The company’s flagship projects are located in the Smackover Formation, a world-class lithium-brine asset, focused in Arkansas and Texas. In partnership with global energy leader Equinor ASA, Standard Lithium is advancing the South West Arkansas Project, a greenfield project located in southern Arkansas, and is actively exploring promising lithium-brine prospects in east Texas. Additionally, the company is advancing the phase 1A project in partnership with LANXESS Corp., a brownfield development project located in southern Arkansas. Standard Lithium also holds an interest in certain mineral leases in the Mojave Desert in San Bernardino County, California. For more information about the company, please visit www.StandardLithium.com.

NOTE TO INVESTORS: The latest news and updates relating to SLI are available in the company’s newsroom at https://ibn.fm/SLI

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
Editor@InvestorWire.com

InvestorWire is powered by IBN

Telomir Pharmaceuticals (NASDAQ: TELO) announced preclinical findings showing that its telomere-elongating drug, Telomir-1, reduced tumor size by approximately 50% in a prostate cancer animal model. The study demonstrated that Telomir-1 actively suppresses cancer growth while protecting against chemotherapy-induced toxicity when combined with Paclitaxel. Contrary to concerns that telomere-elongating drugs may promote cancer, Telomir-1 selectively benefited healthy cells while inhibiting tumor development. The company is advancing Telomir-1 toward clinical development for oncology and age-related diseases, aiming to submit an Investigational New Drug (IND) application by the end of 2025.

To view the full press release, visit https://ibn.fm/MMub3

About Telomir Pharmaceuticals

Telomir Pharmaceuticals is a preclinical stage pharmaceutical company seeking to lead development in longevity science in both humans and animals. The company is focused on the development of Telomir-1, a novel small molecule designed to lengthen the DNA’s protective telomere caps, which are crucial in the aging process. Telomeres are the protective end caps of a chromosome made up of DNA sequences and proteins. As humans age, telomeres shorten, with metal reactivity accelerating the process, which presents humans and pet animals with an increased chance of contracting a number of degenerative and age-related diseases. Telomir’s goal is to develop, gain regulatory approval for and commercialize Telomir-1, proposed to be dosed orally, with the broader aim of promoting longevity and enhancing overall quality of life. For more information about the company, visit the website www.Telodx.com.

NOTE TO INVESTORS: The latest news and updates relating to TELO are available in the company’s newsroom at https://ibn.fm/TELO

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
Editor@InvestorWire.com

InvestorWire is powered by IBN

Oragenics (NYSE American: OGEN) announced the filing of its Annual Report on Form 10-K for the year ended Dec. 31, 2024, with the U.S. Securities and Exchange Commission on March 14, 2025. The company’s audited financial statements received an unqualified audit opinion, though an explanatory paragraph raised concerns about its ability to continue as a going concern. Oragenics remains focused on advancing its pipeline of treatments for concussion and brain-related health conditions while pursuing strategic opportunities to ensure long-term growth. Further details are available in Footnote 1 of the financial statements.

To view the full press release, visit https://ibn.fm/BrTCE

About Oragenics

Oragenics is a development-stage biotechnology company focused on nasal delivery of pharmaceutical medications in neurology and fighting infectious diseases, including drug candidates for treating mild traumatic brain injury (“mTBI”), also known as concussion, and for treating Niemann Pick Disease Type C (“NPC”), as well as proprietary powder formulation and an intranasal delivery device. For more information, visit the company’s website at www.Oragenics.com

NOTE TO INVESTORS: The latest news and updates relating to OGEN are available in the company’s newsroom at https://ibn.fm/OGEN

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
Editor@InvestorWire.com

InvestorWire is powered by IBN

G Mining Ventures Corp. (TSX: GMIN) (OTCQX: GMINF) announced that its common shares have been included in several major stock indices, including the NYSE Arca Gold Miners Index (GDX), MVIS Global Junior Gold Miners Index (GDXJ), S&P/TSX Composite Index (GSPTSE), and iShares MSCI Canada ETF (EWC). President and CEO Louis-Pierre Gignac stated that the inclusions reflect the company’s commitment to executing its self-perform approach and advancing its gold projects, including the Tocantinzinho Gold Mine. These index additions are expected to enhance trading liquidity and attract institutional investment. The rebalancing for GDX, GDXJ, and GSPTSE is set for March 21, 2025, while EWC was rebalanced on Feb. 28, 2025.

To view the full press release, visit https://ibn.fm/3hncq

About G Mining Ventures Corp.

G Mining Ventures Corp. is a mining company engaged in the acquisition, exploration and development of precious metal projects to capitalize on the value uplift from successful mine development. GMIN is well-positioned to grow into the next mid-tier precious metals producer by leveraging strong access to capital and proven development expertise. GMIN is currently anchored by the Tocantinzinho Gold Mine (” TZ “) in Brazil and Oko West Project in Guyana , both mining friendly and prospective jurisdictions.

NOTE TO INVESTORS: The latest news and updates relating to GMINF are available in the company’s newsroom at https://ibn.fm/GMINF

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
Editor@InvestorWire.com

InvestorWire is powered by IBN

Tonix Pharmaceuticals (NASDAQ: TNXP) announced its fourth-quarter and full-year 2024 financial results, alongside key operational updates. The company highlighted preparations for the potential commercial launch of TNX-102 SL for fibromyalgia in Q4 2025, pending FDA approval with a PDUFA date set for Aug. 15, 2025. Tonix remains debt-free, with cash resources projected to support operations into early 2026. The company also reported progress across its pipeline, including TNX-1500 for kidney transplant rejection, TNX-801 for mpox and smallpox, and TNX-1300 for cocaine intoxication. For Q4 2024, net product revenue reached $2.6 million, while the company reported a net loss of $22.1 million. Full-year 2024 net loss was $130 million, with R&D expenses reduced to $40 million from $86.7 million in 2023 due to pipeline prioritization.

To view the full press release, visit https://ibn.fm/JhUrr

About Tonix Pharmaceuticals Holding Corp.

Tonix is a fully integrated biopharmaceutical company focused on transforming therapies for pain management and modernizing solutions for public health challenges. Tonix’s priority is to submit a New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) this month for TNX-102 SL, a product candidate for which two statistically significant phase 3 studies have been completed for the management of fibromyalgia. TNX-102 SL was generally well tolerated in the phase 3 program. The FDA has granted Fast Track designation to TNX-102 SL for the management of fibromyalgia. TNX-102 SL is also being developed to treat acute stress reaction. Tonix recently announced that the U.S. Department of Defense (“DoD”), Defense Threat Reduction Agency (“DTRA”) awarded it a contract for up to $34 million over five years to develop TNX-4200, small molecule broad-spectrum antiviral agents targeting CD45 for the prevention or treatment of infections to improve the medical readiness of military personnel in biological threat environments. Tonix owns and operates a state-of-the art infectious disease research facility in Frederick, Maryland. The company’s Good Manufacturing Practice (“GMP”)-capable advanced manufacturing facility in Dartmouth, Maryland, was purpose-built to manufacture TNX-801, and the GMP suites are ready to be reactivated in case of a national or international emergency. Tonix’s development portfolio is focused on central nervous system (“CNS”) disorders. Tonix’s CNS portfolio includes TNX-1300 (cocaine esterase), a biologic in Phase 2 development designed to treat cocaine intoxication that has Breakthrough Therapy designation. Tonix’s immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease. Tonix Medicines, the company’s commercial subsidiary, markets Zembrace(R) SymTouch(R) (sumatriptan injection) 3 mg and Tosymra(R)(sumatriptan nasal spray) 10 mg for the treatment of acute migraine with or without aura in adults. For more information about the company, please visit www.TonixPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to TNXP are available in the company’s newsroom at https://ibn.fm/TNXP

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
Editor@InvestorWire.com

InvestorWire is powered by IBN

Trump Media & Technology Group (NASDAQ: DJT) has experienced a significant downturn, with its stock price plummeting 50% since President Donald Trump’s inauguration. The shares closed at a five-month low of $19.17 last week, reflecting broader market challenges. ​

As of 11:48 AM EST on March 18, 2025, DJT’s stock is trading at $20.06, reflecting a decrease of $0.50 (2.43%) from the previous close.​

To view the full article, visit https://ibn.fm/ZO2Dh

About Trump Media & Technology Group Corp.

Trump Media & Technology Group Corp. is a media and technology company founded by former President Donald Trump. The company aims to provide social media platforms and technology solutions that promote free speech and counter perceived biases in mainstream media. Its flagship product, Truth Social, is a social media platform designed to encourage open and honest dialogue among users. Through its innovative approach, the company seeks to redefine the media landscape and provide alternative platforms for communication and information sharing.​

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
Editor@InvestorWire.com

InvestorWire is powered by IBN

Microsoft (NASDAQ: MSFT)  has launched Office 2024 Home & Business for both Mac and PC, offering users a lifetime license as an alternative to the subscription-based Microsoft 365. This version includes essential applications such as Word, Excel, PowerPoint, Outlook, and OneNote. Notably, the 2024 edition integrates AI features like Word’s Smart Compose, providing intelligent suggestions to enhance productivity.

As of 11:41 AM EST on March 18, 2025, Microsoft’s stock (NASDAQ: MSFT) is trading at $382.31, reflecting a decrease of $6.39 (1.64%) from the previous close.​

To view the full article, visit https://ibn.fm/XWyoA

About Microsoft Corporation

Microsoft Corporation is a leading global technology company, renowned for developing, licensing, and supporting a wide range of software products, services, and devices. Founded in 1975 and headquartered in Redmond, Washington, Microsoft’s mission is to empower every person and organization on the planet to achieve more. The company’s extensive product portfolio includes the Windows operating system, Microsoft Office suite, Azure cloud computing services, and Surface hardware devices. Through continuous innovation and commitment to excellence, Microsoft strives to deliver cutting-edge solutions that enhance productivity and drive digital transformation worldwide.

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
Editor@InvestorWire.com

InvestorWire is powered by IBN

Knightscope (NASDAQ: KSCP), a developer of autonomous security robots and AI technologies, has formally submitted public comments to the White House’s AI Action Plan, emphasizing the need for AI-powered security solutions in federal facilities and critical infrastructure. The company’s recommendations include modernizing procurement policies, launching multi-agency pilot programs, and restricting the purchase of autonomous security robots from adversary nations. CEO William Santana Li highlighted the role of AI-driven security in enhancing public safety while reducing costs. Knightscope’s technology aims to strengthen national security by providing continuous situational awareness and acting as a force multiplier for human security personnel.

To view the full press release, visit https://ibn.fm/8ucMy

About Knightscope, Inc.

Knightscope builds cutting-edge technologies to improve public safety. The company’s long-term ambition is to make the United States of America the safest country in the world. For more information about the company, please visit www.Knightscope.com.

NOTE TO INVESTORS: The latest news and updates relating to KSCP are available in the company’s newsroom at https://ibn.fm/KSCP

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
Editor@InvestorWire.com

InvestorWire is powered by IBN

Trillion Energy (CSE: TCF) (OTCQB: TRLEF) has provided an operational update on its SASB offshore gas project in Turkey, highlighting the successful installation of velocity string tubing in six wells to improve production efficiency. The company has also initiated nitrogen injection to stimulate gas output, with positive results confirming the effectiveness of water reduction measures. To sustain long-term production, Trillion has secured a gas lift compressor for the Akcakoca platform, with onshore testing set to begin March 24 before mobilization the following week. Additional pump solutions, including a Progressive Cavity Pump and Electric Submersible Pumps, will further optimize well performance in the coming months.

To view the full article, visit https://ibn.fm/sRfmZ

About Trillion Energy International Inc.

Trillion Energy is focused on oil and natural gas production for Europe and Türkiye with natural gas assets in Türkiye. The company holds a 49% interest in the SASB natural gas field, a Black Sea natural gas development and 19.6% (except three wells with 9.8%) interest in the Cendere oil field. The company also is pursuing oil exploration in S.E. Turkiye and beyond. More information may be found on www.sedar.com and the company’s website.

NOTE TO INVESTORS: The latest news and updates relating to TRLEF are available in the company’s newsroom at https://ibn.fm/TRLEF

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
Editor@InvestorWire.com

InvestorWire is powered by IBN

TC BioPharm (NASDAQ: TCBP), a clinical-stage biotechnology company developing allogeneic gamma-delta T cell therapies, is implementing a strategic shift to a decentralized model, outsourcing key functions to contract development and manufacturing organizations (CDMOs). The transition is expected to reduce operational costs by approximately 55% compared to 2024, with estimated annual savings of $4.2 million. As part of this restructuring, the company will reduce its workforce by around 20 employees, primarily in production and quality divisions. CEO Bryan Kobel emphasized that the move positions TC BioPharm for future clinical trials and advancements in cell therapy manufacturing.

To view the full press release, visit: https://ibn.fm/XTB48

About TC BioPharm Holdings PLC

TC BioPharm is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cell therapies for the treatment of cancer with human efficacy data in acute myeloid leukemia. Gamma-delta T cells are naturally occurring immune cells that embody properties of both the innate and adaptive immune systems and can intrinsically differentiate between healthy and diseased tissue. TC BioPharm is the leader in developing gamma-delta T cell therapies, and the first company to conduct phase II/pivotal clinical studies in oncology. The company is conducting two investigator-initiated clinical trials for its unmodified gamma-delta T cell product line – Phase 2b/3 pivotal trial for OmnImmune(R) in treatment of acute myeloid leukemia using the company’s proprietary allogeneic CryoTC technology to provide frozen product to clinics worldwide. For more information about the company, visit www.tcbioparm.com.

NOTE TO INVESTORS: The latest news and updates relating to TCBP are available in the company’s newsroom at https://ibn.fm/TCBP

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
Editor@InvestorWire.com

InvestorWire is powered by IBN

Aditxt (NASDAQ: ADTX) through its wholly owned subsidiary Adivir, Inc., is progressing with its planned acquisition of Appili Therapeutics (TSX: APLI; OTCPink: APLIF) under a court-approved plan of arrangement. Appili shareholders have overwhelmingly approved the transaction, and the company has secured all necessary court approvals. The closing remains contingent on Aditxt securing sufficient financing, with an extension granted until March 31, 2025, in exchange for a $250,000 payment. Separately, Appili has applied for up to $117.5 million in U.S. federal funding to support infectious disease treatments, further positioning the company within the critical biopharmaceutical sector.

To view the full press release, visit https://ibn.fm/ShJYL

About Aditxt Inc.

Aditxt is an innovation platform dedicated to accelerating promising health innovations. Aditxt’s ecosystem of research institutions, industry partners and shareholders collaboratively drives its mission to “Make Promising Innovations Possible Together.” The innovation platform is the cornerstone of Aditxt’s strategy, where multiple disciplines drive disruptive growth and address significant societal challenges. Aditxt operates a unique model that democratizes innovation, ensures every stakeholder’s voice is heard and valued, and empowers collective progress. Aditxt currently operates two programs focused on immune health and precision health. The company plans to introduce two additional programs dedicated to public health and women’s health. For these, Aditxt has entered into an arrangement agreement with Appili Therapeutics Inc. (TSX: APLI) (OTC: APLIF), which focuses on infectious diseases, and a merger agreement with Evofem. Each program will be designed to function autonomously while collectively advancing Aditxt’s mission of discovering, developing and deploying innovative health solutions to tackle some of the most urgent health challenges. The closing of the transactions with Appili and Evofem is subject to several conditions, including but not limited to approval of the transactions by the respective target shareholders and Aditxt raising sufficient capital to fund its obligations at closing. No assurance can be given that all of the conditions to closing will be obtained or satisfied or that either of the transactions will ultimately close. For more information, please visit www.Aditxt.com.

NOTE TO INVESTORS: The latest news and updates relating to ADTX are available in the company’s newsroom at https://ibn.fm/ADTX

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
Editor@InvestorWire.com

InvestorWire is powered by IBN

Energy Fuels (NYSE American: UUUU) (TSX: EFR) and Chemours (NYSE: CC) have announced a strategic alliance to enhance domestic rare earth and critical mineral supply chains. The collaboration builds on their existing relationship, leveraging Energy Fuels’ rare earth element production and Chemours’ heavy mineral sands mining operations in Florida and Georgia. The companies aim to bolster U.S. production of rare earth elements, titanium, and zirconium, reducing reliance on foreign sources. Executives from both firms, along with government officials, highlighted the agreement’s role in strengthening national security and economic stability.

To view the full press release, visit https://ibn.fm/ONEK9

About Energy Fuels Inc.

Energy Fuels is a leading U.S.-based critical minerals company, focused on uranium, rare earth elements (“REEs”), heavy mineral sands (“HMS”), vanadium and medical isotopes. The company has been the leading U.S. producer of natural uranium concentrate for the past several years, which is sold to nuclear utilities that process it further for the production of carbon-free nuclear energy, and owns and operates several conventional and in siturecovery uranium projects in the western United States. Energy Fuels also owns the White Mesa Mill in Utah, which is the only fully licensed and operating conventional uranium processing facility in the United States. At the mill, the company also produces advanced REE products and vanadium oxide (when market conditions warrant), and is preparing to begin pilot-scale recovery of certain medical isotopes from existing uranium process streams needed for emerging cancer treatments. The company also owns the operating Kwale HMS project in Kenya, which is nearing the end of its life, and is developing three additional HMS projects, including the Toliara Project in Madagascar, the Bahia Project in Brazil and the Donald Project in Australia, in which Energy Fuels has the right to earn up to a 49% interest in a joint venture with Astron Corporation Limited. The company is based in Lakewood, Colorado, with its heavy-mineral sands operations managed from Perth, Australia. For more information, visit the company’s website at www.EnergyFuels.com.

NOTE TO INVESTORS: The latest news and updates relating to UUUU are available in the company’s newsroom at http://ibn.fm/UUUU

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
Editor@InvestorWire.com

InvestorWire is powered by IBN

D-Wave Quantum Inc. (NYSE: QBTS) (“D-Wave”), a leader in quantum computing systems, software, and services, has announced its financial results for fourth quarter and year-end 2024, with a 128% year-over-year increase in bookings, reaching $23.9 million in bookings for the year ended December 31, 2024. The company also announced a consolidated cash balance that now exceeds $300 million.

“Every day D-Wave’s quantum technology is helping customers gain competitive advantages, discover new scientific breakthroughs, and fuel innovations that were previously unimaginable,” said Dr. Alan Baratz, CEO of D-Wave. “Our mission is unwavering – to help organizations realize the benefits of quantum computing now. With record bookings, a record cash position and an unequivocal demonstration of our quantum system outperforming classical on a real-world problem, our progress toward achieving that mission is clear.”

To review the details of D-Wave’s business performance and its latest advancements in quantum computing, view the press release: https://ibn.fm/qrWiT

 About D-Wave Quantum Inc.

D-Wave is a leader in the development and delivery of quantum computing systems, software, and services. We are the world’s first commercial supplier of quantum computers, and the only company building both annealing and gate-model quantum computers. Our mission is to help customers realize the value of quantum, today. Our 5,000+ qubit Advantage^TM quantum computers, the world’s largest, are available on-premises or via the cloud, supported by 99.9% availability and uptime. More than 100 organizations trust D-Wave with their toughest computational challenges. With over 200 million problems submitted to our Advantage and Advantage2^TM systems to date, our customers apply our technology to address use cases spanning optimization, artificial intelligence, research and more. Learn more about realizing the value of quantum computing today and how we’re shaping the quantum-driven industrial and societal advancements of tomorrow: www.dwavequantum.com.

NOTE TO INVESTORS: The latest news and updates relating to QBTS are available in the company’s newsroom at https://ibn.fm/QBTS

Forward Looking Statements

Certain statements in this press release are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management’s control, including the risks set forth under the heading “Risk Factors” discussed under the caption “Item 1A. Risk Factors” in Part I of our most recent Annual Report on Form 10-K or any updates discussed under the caption “Item 1A. Risk Factors” in Part II of our Quarterly Reports on Form 10-Q and in our other filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this press release in making an investment decision, which are based on information available to us on the date hereof. We undertake no duty to update this information unless required by law.

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
Editor@InvestorWire.com

InvestorWire is powered by IBN

• Brera Holdings, an Ireland-based, international holding company focused on expanding its global portfolio of men’s and women’s sports s, has announced the appointment of Dr. Arthur B. Laffer to its Advisory Board.
• With an economic lens, Dr. Laffer can provide strategic guidance on securing high-value sponsorship agreements, optimizing broadcasting rights negotiations, and leveraging government incentives to support Brera’s global expansion. Additionally, Dr. Laffer may help refine Brera’s financial modeling for player salary structures, transfer market efficiency, and overall profitability.
• Dr. Laffer’s appointment points to Brera’s ambitions for the 2025 calendar year and follows the company’s recent investment in a Mozambican football club, along with 10 new signings in the 2024-2025 winter transfer window.

Brera Holdings (NASDAQ: BREA), an Ireland-based, international holding company focused on expanding its global portfolio of men’s and women’s sports clubs through a multi-club ownership (“MCO”) approach, has announced the addition of Dr. Arthur B. Laffer to its Advisory Board. His strategic input to the company can help develop Brera’s proprietary financial models to optimize player salaries, transfer fees, and overall profitability. In addition, his corporate and political networks could be integral in positioning Brera’s clubs as transatlantic brands, providing exposure to American investors (https://ibn.fm/J5alM).

“Dr. Laffer’s economic expertise and strategic insights into market expansion and asset monetization make him a powerful addition to our all-star Advisory Board,” noted Daniel McClory, Brera’s Executive Chairman. “His principles, including the Laffer Curve, offer a unique perspective on optimizing…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to BREA are available in the company’s newsroom at https://ibn.fm/BREA

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
Editor@InvestorWire.com

SKYX Platforms (NASDAQ: SKYX), an advanced smart home technology company, reported record fourth-quarter revenue of $23.7 million, continuing its consistent growth throughout 2024. The company also secured an additional $1 million in preferred funding, bringing its total to $12 million. SKYX is expanding its smart plug & play technology across major retail and professional segments, aiming to reach 20,000 homes by the end of Q1 2025. Recent strategic moves include partnerships with Cavco Homes and Forte Developments, a collaboration with Wayfair, and leadership additions to drive e-commerce and product expansion.

To view the full press release, visit https://ibn.fm/bNcbb

About SKYX Platforms Corp.

As electricity is a standard in every home and building, our mission is to make homes and buildings become safe-advanced and smart as the new standard. SKYX has a series of highly disruptive advanced-safe-smart platform technologies, with over 97 U.S. and global patents and patent pending applications. Our technologies place an emphasis on high quality and ease of use, while significantly enhancing both safety and lifestyle in homes and buildings. We believe that our products are a necessity in every room in both homes and other buildings in the U.S. and globally. For more information, please visit our website at https://skyplug.com/ or follow us on LinkedIn.

NOTE TO INVESTORS: The latest news and updates relating to SKYX are available in the company’s newsroom at https://ibn.fm/SKYX

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
Editor@InvestorWire.com

InvestorWire is powered by IBN

Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company specializing in inflammation and immunology (I&I) biological products and contract development and manufacturing (CDMO) services, announced its participation in the BIO-Europe Spring 2025 conference from March 17-19 in Milan, Italy. The company’s leadership will meet with potential pharmaceutical partners, prospective CDMO clients, and institutional investors to showcase its innovative NanoAb pipeline and biologics manufacturing capabilities. Scinai will also exhibit its CDMO services at booth #22.

To view the full press release, visit https://ibn.fm/HOtTh

About Scinai Immunotherapeutics Ltd.

Scinai is a biopharmaceutical company with two complementary business units. One is focused on in-house development of inflammation and immunology (“I&I”) biological therapeutic products beginning with an innovative, de-risked pipeline of nanosized VHH antibodies (“NanoAbs”) targeting diseases with large unmet medical needs. The second business unit is a boutique CDMO providing biological drug development, analytical methods development, clinical GMP manufacturing, and preclinical and clinical trial design and execution services to early stage biotech companies. For more information, visit the company’s website at www.Scinai.com.

NOTE TO INVESTORS: The latest news and updates relating to SCNI are available in the company’s newsroom at https://ibn.fm/SCNI

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
Editor@InvestorWire.com

InvestorWire is powered by IBN

Energy Fuels (NYSE American: UUUU) (TSX: EFR), a leading U.S. producer of uranium, rare earth elements (REE), and heavy mineral sands, announced the signing of a strategic Memorandum of Understanding (MOU) with South Korea-based POSCO International Corporation. The agreement outlines a collaboration aimed at establishing a new non-China REE supply chain for electric vehicle (EV) and hybrid EV drivetrains for automakers in the U.S., E.U., Japan, and South Korea. Initial samples of Energy Fuels’ neodymium-praseodymium (NdPr) oxide from its White Mesa Mill in Utah have met POSCO’s specifications. If validated, Energy Fuels could supply NdPr oxide for mass production later this year, supporting the manufacturing of high-performance REE magnets.

To view the full press release, visit https://ibn.fm/bYfYF

About Energy Fuels Inc.

Energy Fuels is a leading U.S.-based critical minerals company, focused on uranium, rare earth elements (“REEs”), heavy mineral sands (“HMS”), vanadium and medical isotopes. The company has been the leading U.S. producer of natural uranium concentrate for the past several years, which is sold to nuclear utilities that process it further for the production of carbon-free nuclear energy, and owns and operates several conventional and in siturecovery uranium projects in the western United States. Energy Fuels also owns the White Mesa Mill in Utah, which is the only fully licensed and operating conventional uranium processing facility in the United States. At the mill, the company also produces advanced REE products and vanadium oxide (when market conditions warrant), and is preparing to begin pilot-scale recovery of certain medical isotopes from existing uranium process streams needed for emerging cancer treatments. The company also owns the operating Kwale HMS project in Kenya, which is nearing the end of its life, and is developing three additional HMS projects, including the Toliara Project in Madagascar, the Bahia Project in Brazil and the Donald Project in Australia, in which Energy Fuels has the right to earn up to a 49% interest in a joint venture with Astron Corporation Limited. The company is based in Lakewood, Colorado, with its heavy-mineral sands operations managed from Perth, Australia. For more information, visit the company’s website at www.EnergyFuels.com.

NOTE TO INVESTORS: The latest news and updates relating to UUUU are available in the company’s newsroom at http://ibn.fm/UUUU

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
Editor@InvestorWire.com

InvestorWire is powered by IBN

Fifty 1 Labs (OTC: FITY), formerly Consumer Automotive Finance Inc. (OTC: CAFI), has successfully completed its name and ticker symbol change, now officially trading as FITY on the OTC market. This marks a significant milestone as the company continues executing its strategic growth initiatives. In addition, the company has responded to a second round of comments in its ongoing efforts to regain compliance with SEC Rule 15c2-11.

“We are excited about the progress we’ve made in solidifying our brand identity and strengthening our market position,” said Brandon Spikes, CEO of Fifty 1 Labs. “Finalizing our name and symbol change represents an important step forward as we continue executing on our long-term vision. Additionally, regaining our 15c2-11 compliance remains a top priority, as it is essential for providing greater transparency and liquidity for our shareholders.”

To view the full press release, visit https://ibn.fm/oitQm

About Fifty 1 Labs Inc.

Fifty 1 Labs is a leading innovator in the sports supplement, fitness equipment, and health and wellness industries. The company is focused on delivering high-quality products designed to enhance performance, well-being, and overall lifestyle. With a strategic vision for growth, the company operates four key subsidiaries: 51, LLC, which specializes in sports supplements; The Quickness, which offers patented athletic training equipment; Astound NMN, a leader in anti-aging and DNA repair supplements; and Drago Knives, patented knife throwing technology. Fifty 1 Labs is also actively pursuing strategic acquisitions to expand its portfolio and drive sustainable growth.

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
Editor@InvestorWire.com

InvestorWire is powered by IBN